Every major pharmaceutical and biotech company at a medical congress has made a series of deliberate decisions before a single attendee walks through the exhibit hall doors. How large a footprint to take. Where on the floor to position it. What messaging to put on the largest visible surface. Which data to feature. What materials to hand to every HCP who stops to engage. What to have booth personnel say, and what not to say.
Each of those decisions was reviewed and approved at a senior level. Each reflects a considered judgment about how the company wants to be perceived by the clinical community in that room. Taken together, they constitute one of the clearest windows into a competitor’s commercial positioning strategy available at any congress, and one of the least systematically captured.
What systematic booth analysis actually captures
Size and location are the starting point. A competitor who has significantly expanded their footprint since the prior year is communicating something about commercial investment and organizational priority. A competitor who has downsized is communicating something else. Location choices on a congress floor are not accidental; premium positioning near high-traffic entrances and session corridors carries a cost that only gets approved when the commercial rationale is clear.
Messaging and claims language on booth graphics reveal how a company is positioning its asset with the HCPs most likely to prescribe it. Which clinical outcomes they lead with, which patient populations they emphasize, how they frame comparisons with existing standards of care, and what language they use to characterize safety or tolerability: all of it has been tested, reviewed, and approved before it goes on display at a congress attended by thousands of physicians.
Printed and digital materials distributed at the booth often go further than the graphics. Detail aids, clinical reprints, patient case handouts, and QR-linked content represent a second layer of messaging, typically more detailed and more directly commercial than what appears on display surfaces. Systematic collection and review of everything available at a competitor’s booth produces a snapshot of their current promotional strategy that no secondary source replicates.
Booth personnel conversations: the intelligence layer most programs miss entirely
Competitor booth personnel, including medical science liaisons, commercial team members, and in some cases clinical staff, are present specifically to engage with HCPs. Those conversations reveal how a company is talking about its product in a live commercial context: what objections they are trained to address, how they are framing competitor comparisons, what clinical evidence they are leaning on most heavily, and occasionally, what they are being coached not to discuss.
These conversations must always be conducted transparently, without misrepresentation, and in strict alignment with company policies and industry compliance standards. Managed correctly, and conducted by experienced analysts who know what to listen for, they produce intelligence about real-time commercial execution that no abstract, no publication, and no secondary monitoring program can surface. It is also intelligence that is only available during the event. Once the congress ends, that window closes.
Why it gets skipped anyway
Booth analysis gets treated as supplementary rather than core in most coverage programs for a practical reason: session attendance fills the calendar, and the exhibit hall competes for time against a schedule that is already tight. The implicit assumption is that booth intelligence is less rigorous, less structured, and therefore less valuable than documented session data.
That assumption inverts the actual value hierarchy. What a competitor presented in a session is documented in an abstract available to everyone before the conference began. What they chose to put on their booth, what they are actively saying to physicians on the floor, and how they are positioning themselves commercially in real time: none of that is in the abstract book. A coverage program designed to capture only what is already publicly documented produces marginal intelligence advantage. Structured booth analysis is one of the clearest ways to move beyond that.
For a full look at how booth analysis fits within a structured three-stage conference coverage program, alongside session documentation, primary KOL research, and post-conference synthesis, see Sedulo’s complete guide to pharmaceutical conference coverage.